140 related articles for article (PubMed ID: 11249721)
1. CP-101606 Pfizer Inc.
Chazot PL
Curr Opin Investig Drugs; 2000 Nov; 1(3):370-4. PubMed ID: 11249721
[TBL] [Abstract][Full Text] [Related]
2. Effects of pan- and subtype-selective N-methyl-D-aspartate receptor antagonists on cortical spreading depression in the rat: therapeutic potential for migraine.
Peeters M; Gunthorpe MJ; Strijbos PJ; Goldsmith P; Upton N; James MF
J Pharmacol Exp Ther; 2007 May; 321(2):564-72. PubMed ID: 17267580
[TBL] [Abstract][Full Text] [Related]
3. Valdecoxib (Pharmacia).
Gotta AW
Curr Opin Investig Drugs; 2002 Feb; 3(2):240-5. PubMed ID: 12020053
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological characterization of Ro 63-1908 (1-[2-(4-hydroxy-phenoxy)-ethyl]-4-(4-methyl-benzyl)-piperidin-4-ol), a novel subtype-selective N-methyl-D-aspartate antagonist.
Gill R; Alanine A; Bourson A; Buttelmann B; Fischer G; Heitz MP; Kew JN; Levet-Trafit B; Lorez HP; Malherbe P; Miss MT; Mutel V; Pinard E; Roever S; Schmitt M; Trube G; Wybrecht R; Wyler R; Kemp JA
J Pharmacol Exp Ther; 2002 Sep; 302(3):940-8. PubMed ID: 12183650
[TBL] [Abstract][Full Text] [Related]
5. Late phase of long-term potentiation induced by co-application of N-methyl-d-aspartic acid and the antagonist of NR2B-containing N-methyl-d-aspartic acid receptors in rat hippocampus.
Oh-Nishi A; Saji M; Satoh SZ; Ogata M; Suzuki N
Neuroscience; 2009 Mar; 159(1):127-35. PubMed ID: 19010396
[TBL] [Abstract][Full Text] [Related]
6. Renaissance of NMDA receptor antagonists: do they have a role in the pharmacotherapy for alcoholism?
Nagy J
IDrugs; 2004 Apr; 7(4):339-50. PubMed ID: 15057640
[TBL] [Abstract][Full Text] [Related]
7. The effect of CGX-1007 and CI-1041, novel NMDA receptor antagonists, on NMDA receptor-mediated EPSCs.
Barton ME; White HS; Wilcox KS
Epilepsy Res; 2004 Mar; 59(1):13-24. PubMed ID: 15135163
[TBL] [Abstract][Full Text] [Related]
8. N-methyl-D-aspartate receptor-dependent long-term potentiation in CA1 region affects synaptic expression of glutamate receptor subunits and associated proteins in the whole hippocampus.
Zhong WX; Dong ZF; Tian M; Cao J; Xu L; Luo JH
Neuroscience; 2006 Sep; 141(3):1399-413. PubMed ID: 16766131
[TBL] [Abstract][Full Text] [Related]
9. Duloxetine Eli Lilly & Co.
Pitsikas N
Curr Opin Investig Drugs; 2000 Sep; 1(1):116-21. PubMed ID: 11249587
[TBL] [Abstract][Full Text] [Related]
10. The chemical biology of clinically tolerated NMDA receptor antagonists.
Chen HS; Lipton SA
J Neurochem; 2006 Jun; 97(6):1611-26. PubMed ID: 16805772
[TBL] [Abstract][Full Text] [Related]
11. The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease.
Nash JE; Ravenscroft P; McGuire S; Crossman AR; Menniti FS; Brotchie JM
Exp Neurol; 2004 Aug; 188(2):471-9. PubMed ID: 15246846
[TBL] [Abstract][Full Text] [Related]
12. Norastemizole Sepracor.
Bachmann KA
Curr Opin Investig Drugs; 2000 Oct; 1(2):219-26. PubMed ID: 11249577
[TBL] [Abstract][Full Text] [Related]
13. GMP prevents excitotoxicity mediated by NMDA receptor activation but not by reversal activity of glutamate transporters in rat hippocampal slices.
Molz S; Tharine DC; Decker H; Tasca CI
Brain Res; 2008 Sep; 1231():113-20. PubMed ID: 18655777
[TBL] [Abstract][Full Text] [Related]
14. Memantine. Merz.
Kilpatrick GJ; Tilbrook GS
Curr Opin Investig Drugs; 2002 May; 3(5):798-806. PubMed ID: 12090556
[TBL] [Abstract][Full Text] [Related]
15. Phenylethanolamines inhibit NMDA receptors by enhancing proton inhibition.
Mott DD; Doherty JJ; Zhang S; Washburn MS; Fendley MJ; Lyuboslavsky P; Traynelis SF; Dingledine R
Nat Neurosci; 1998 Dec; 1(8):659-67. PubMed ID: 10196581
[TBL] [Abstract][Full Text] [Related]
16. Gacyclidine (Beaufour-Ipsen).
Mitha AP; Maynard KI
Curr Opin Investig Drugs; 2001 Jun; 2(6):814-9. PubMed ID: 11572662
[TBL] [Abstract][Full Text] [Related]
17. Neuroprotection by tosyl-polyamine derivatives through the inhibition of ionotropic glutamate receptors.
Masuko T; Namiki R; Nemoto Y; Miyake M; Kizawa Y; Suzuki T; Kashiwagi K; Igarashi K; Kusama T
J Pharmacol Exp Ther; 2009 Nov; 331(2):522-30. PubMed ID: 19644042
[TBL] [Abstract][Full Text] [Related]
18. Donepezil attenuates excitotoxic damage induced by membrane depolarization of cortical neurons exposed to veratridine.
Akasofu S; Sawada K; Kosasa T; Hihara H; Ogura H; Akaike A
Eur J Pharmacol; 2008 Jul; 588(2-3):189-97. PubMed ID: 18508044
[TBL] [Abstract][Full Text] [Related]
19. NR2B selective NMDA receptor antagonist CP-101,606 prevents levodopa-induced motor response alterations in hemi-parkinsonian rats.
Wessell RH; Ahmed SM; Menniti FS; Dunbar GL; Chase TN; Oh JD
Neuropharmacology; 2004 Aug; 47(2):184-94. PubMed ID: 15223297
[TBL] [Abstract][Full Text] [Related]
20. Exubera. Inhale therapeutic systems.
Bindra S; Cefalu WT
Curr Opin Investig Drugs; 2002 May; 3(5):758-62. PubMed ID: 12090549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
